Bionexus Gene Lab Corporation officially approved its Ethereum-centric financial strategy on Wednesday, becoming the first NASDAQ registered company to prioritize Ethereum only as a strategic asset.
With its announcement, the tech company adopted by Wyoming released a white paper on its Ethereum strategy, detailing why it would choose Ethereum over Bitcoin, which is more commonly adopted for corporate financial management.
“Bitcoin is still a valuable and powerful repository, but Ethereum offers a wider range of utilities Programmable financial platform,” the company wrote White Paperreleased on Wednesday.
Bionexus promotes Ethereum's yield capabilities through staking as a more important advantage over Bitcoin, despite the latter adoption by institutional investors last year.
“Unlike Bitcoin, Ethereum provides additional revenue streams through staking. The stake mechanism of Ethereum proof allows holders to generate 3-5% annual yields,” the company said in its white paper, adding that it could potentially turn Ethereum from a passive asset into an income-generating financial instrument.”
Bionexus points out the institutional reliability of Ethereum as another factor, and points out that the adoption of Ethereum by major financial institutions such as BlackRock and Fidelity examines “long-term potential as a financial product.”
“Our goal is to strategically position Ethereum as a core component of the Treasury over time,” said Sam Tan, CEO of Bionexus. Decryption in an emailed statement. “We can see that our board approval provides flexibility. We intend to allocate a meaningful portion of our reserves to Ethereum.”
Tan refused to disclose the exact percentage of Ethereum allocation “at this stage,” but said the company's team has been “preparing for this shift for a while.”
“We are currently considering whether to run our own validator node or partner with established third-party staking providers,” Tan said. “Our choices depend on security, efficiency and compliance. We'll finalize this as we expand our Ethereum holdings.”
The company also cites Ethereum's role in the global financial system, claiming that the network “supports trillions of Stablecoin Transactions each year and serves as the payment layer for USDT, USDC and other Stablecoins.”
Bionexus' Ethereum Strategy Whitepaper specifically refers to future references Upgrading the Pectra Protocolviews Ethereum's height as something that can be strengthened “as a reliable long-term infrastructure for businesses.”
Despite optimism, there is a Pectra update Issues faced In recent weeks, running early on Wednesday during the Sepoliattest network, and including as well Obstacles From the previous Holesky Test Phase.
Bionexus is operated primarily in Asia through its Malaysian subsidiary, working on genomic diagnosis and chemical distribution.
Industrial chemical provision in the automotive and aerospace sector accounts for 90% of total revenue. We also developed RNA-based blood tests for early detection of cancer and inflammatory diseases, segments representing 10% of revenue.
But with all the outlook with Ethereum, it appears that Bionexus is fighting its own financial challenges.
Last December, the company I received it NASDAQ will notify you that you do not violate the minimum $1 bid price rule.
A temporary exception was granted and compliance was restored until May 1, 2025. To address this, Bionexus plans to split the reverse stock by April 7, 2025.
The company reported subsequent 12 months of revenue of $9.26 million, with a market capitalization of over $5.88 million and stock trading at $0.32, down 61% per year. data From the Financial Times show.
Edited by Sebastian Sinclair
Daily report Newsletter
Start daily with top news articles now. Plus original features, podcasts, videos and more.
